Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

Felix Bongomin; Richard Kwizera; Emmanuel Mande; Sharley Melissa Aloyo; Beatrice Achan; Martha Namusobya; Senai Goitom Sereke; Charles Batte; Sarah Kiguli; Joseph Baruch Baluku; Moses L Joloba; Bruce J Kirenga

doi:10.4314/ahs.v22i3.54

Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

Felix Bongomin, Richard Kwizera, Emmanuel Mande, Sharley Melissa Aloyo, Beatrice Achan, Martha Namusobya, Senai Goitom Sereke, Charles Batte, Sarah Kiguli, Joseph Baruch Baluku, Moses L Joloba, Bruce J Kirenga

Division of Evolution, Infection and Genomics

Research output: Contribution to journal › Article › peer-review

Abstract

Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.

Original language	English
Pages (from-to)	506-511
Number of pages	6
Journal	African Health Sciences
Volume	22
Issue number	3
DOIs	https://doi.org/10.4314/ahs.v22i3.54
Publication status	Published - Sept 2022

Keywords

Humans
Adult
COVID-19
Immunoglobulin G
Uganda
COVID-19 Drug Treatment
Sensitivity and Specificity
Immunoglobulin M
Antibodies, Viral

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4314/ahs.v22i3.54

Cite this

@article{f0e7455c07964a2bae95b87508ad0646,

title = "Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda",

abstract = "Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.",

keywords = "Humans, Adult, COVID-19, Immunoglobulin G, Uganda, COVID-19 Drug Treatment, Sensitivity and Specificity, Immunoglobulin M, Antibodies, Viral",

author = "Felix Bongomin and Richard Kwizera and Emmanuel Mande and Aloyo, {Sharley Melissa} and Beatrice Achan and Martha Namusobya and Sereke, {Senai Goitom} and Charles Batte and Sarah Kiguli and Baluku, {Joseph Baruch} and Joloba, {Moses L} and Kirenga, {Bruce J}",

note = "{\textcopyright} 2022 Bongomin F et al.",

year = "2022",

month = sep,

doi = "10.4314/ahs.v22i3.54",

language = "English",

volume = "22",

pages = "506--511",

journal = "African Health Sciences",

issn = "1680-6905",

publisher = "Makerere University, Medical School",

number = "3",

}

TY - JOUR

T1 - Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

AU - Bongomin, Felix

AU - Kwizera, Richard

AU - Mande, Emmanuel

AU - Aloyo, Sharley Melissa

AU - Achan, Beatrice

AU - Namusobya, Martha

AU - Sereke, Senai Goitom

AU - Batte, Charles

AU - Kiguli, Sarah

AU - Baluku, Joseph Baruch

AU - Joloba, Moses L

AU - Kirenga, Bruce J

PY - 2022/9

Y1 - 2022/9

N2 - Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.

AB - Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.

KW - Humans

KW - Adult

KW - COVID-19

KW - Immunoglobulin G

KW - Uganda

KW - COVID-19 Drug Treatment

KW - Sensitivity and Specificity

KW - Immunoglobulin M

KW - Antibodies, Viral

U2 - 10.4314/ahs.v22i3.54

DO - 10.4314/ahs.v22i3.54

M3 - Article

C2 - 36910368

SN - 1680-6905

VL - 22

SP - 506

EP - 511

JO - African Health Sciences

JF - African Health Sciences

IS - 3

ER -

Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this